GN-CORPORATION
19.10.2021 08:48:06 CEST | Business Wire | Press release
Alfred Patisenah and Daisy Ramadhani of School of Life Sciences and Technology, Indonesia, won the prestigious Fujio Cup Quiz (FCQ), an active knowledge gaining academic event of NCRM NICHE 2021, on stem cells and regenerative medicine, in a fiercely fought contest among teams representing NIMHANS, Bangalore, India and Kasturba Medical College, the defending champions. Rajalakshmi Engineering College represented by Vigneshwar Ranjan and Vasanta Vaarshini Umapathi came runners in this contest across in three stages with assignments and online live quizzing, conducted since 2006, every October to commemorate the inaugural anniversary of Nichi in Centre for Regenerative Medicine.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211018006087/en/
The virtual event had lectures by Prof. Gary Levy , founder, Training program in regenerative medicine, University of Toronto (www.regenmedcanada.com ) on lessons learnt during the pandemic and arenas of research for tackling future Covid-19 like viruses (https://www.springer.com/gp/book/9781461357759 ), Prof. Kazutoshi Mori , Kyoto University, a Lasker prize awardee (https://www.nature.com/articles/nm.3682 ) on unfolding protein response and endoplasmic reticulum stress (https://elifesciences.org/articles/60970 ) and Prof. Timothy Kieffer , University of British Columbia & CSO of Viacyte Inc., on encapsulated pancreatic islet cell transplantation for diabetes (https://doi.org/10.3389/fendo.2021.642152 ). Covid-19 related research were presented by Dr. Tomohiko Kisaka, Hiroshima University, Dr. Stanley Jeremiah, Yokohama City University (https://jamanetwork.com/journals/jama/fullarticle/2765837 ), Dr. K. Raghavan, JAICARE, Madurai, India (https://www.sciencedirect.com/science/article/pii/S0753332221010271 ), Dr. K. Ramesh Shankar, NHS Trust - Lincolnshire Partnership, London United Kingdom (https://www.jns-journal.com/article/S0022-510X(21)00248-3/fulltext ) and Dr Dedeepiya Devaprasad, who spoke on BREW-COCO method for early prediction of worsening outcome in Covid-19. Prof. Jurgen Hescheler, University of Cologne, Germany, Prof. Naoki Yamamoto, Emeritus Professor, National Centre for Global health and Medicine, Tokyo, Japan and Prof. Pushkala Subramaniam, TN MGR Medical University, India, moderated.
NCRM NICHE an inter-disciplinary event cum innovation platform, spearheading development of novel solutions for Non-alcoholic steatohepatitis (NASH or NAFLD : https://doi.org/10.1101/2021.07.08.451700 ) and for managing neurodevelopmental disorders like Autism Spectrum Disorders (https://doi.org/10.1101/2021.06.28.21259619 ), has started attracting multinational investors. Enso Healthcare DMCC, Dubai, UAE, who have partnered with GN Corporation for this active knowledge gaining academic event, being a part of Enso group, a global conglomerate with diverse interests is envisaging to develop path breaking solutions through futuristic research for prevention and management of lifestyle illnesses and in the domains of anti-aging and longevity.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211018006087/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release
Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d
Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release
New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel
HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 17:30:00 CEST | Press release
HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom